2168561-20-2
2168561-20-2
Chemical Structure
Nurulimab
Synonym(s): BCD-145
- CAS No.: 2168561-20-2
- Formula:N/A
- Molecular Weight:(143.78 kDa)
IUPAC Name: (2R,3R,4S,5R,6R)-6-((benzoyloxy)methyl)-5-hydroxy-2-(1H-indol-1-yl)-4-(phosphonooxy)tetrahydro-2H-pyran-3-yl 2-aminobenzoate
SMILES: [Nurulimab]
Biological Activity: Nurulimab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) human monoclonal antibody. Nurulimab binds to CTLA-4 and blocks its interaction with ligands, stimulating T-cell proliferation, cytokine production, and inducing an antitumor immune response. Nurulimab can be used for the research of unresectable or metastatic melanoma and advanced cutaneous melanoma[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Nurulimab | 95.00% | Nurulimab is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) human monoclonal antibody. Nurulimab binds to CTLA-4 and blocks its interaction with ligands, stimulating T-cell proliferation, cytokine production, and inducing an antitumor immune response. Nurulimab can be used for the research of unresectable or metastatic melanoma and advanced cutaneous melanoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Fedor Kryukov, et al. A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma. J Clin Oncol 42, 9526(2024). Volume 42, Number 16_suppl.
-
[2]. Demidov L, et al. Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial. Eur J Cancer
. 2025 Sep 9:227:115674. [Content Brief]
